Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Osteo-Bi-Flex

This article was originally published in The Tan Sheet

Executive Summary

Ad campaign highlighting new products, packaging of joint health care line to debut April 16 with 30-second TV spots, Rexall Sundown says. Ad agency Crispin Porter Bogusky (Miami) also has designed print ads, which will break in May issues of active lifestyle magazines such as Arthritis Today, Remedy, Golf Digest and Walking. Ads will carry tagline: "Does the bed creak when you get up in the morning, or is that just you?" and suggest consumers "give...joints precisely what they need: A little peace and quiet." Royal Numico subsidiary expects revamped line to broaden brand's appeal; firm has introduced triple-strength formulation of Osteo-Bi-Flex as well as Bone & Joint Care Formula (1"The Tan Sheet" Jan. 22, p. 12)

You may also be interested in...



Osteo-Bi-Flex Relaunch Highlights New Products, Packaging, Pricing

Rexall Sundown is adding several new products to its Osteo-Bi-Flex line of joint health supplements in an attempt to broaden the brand's appeal and boost sales in the face of increased competition in the category.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel